Innovative Multimodal Management with Propranolol, Prednisone, and Pulsed Dye Laser for Ulcerated Infantile Hemangiomas: A Case Series

Babies are born with a remarkable capacity to heal, yet sometimes their own growth spurts turn against them. Among the most common growth anomalies in infancy are benign vascular tumors, known as infantile hemangiomas. These are not cancers, but rather overgrowths of blood vessels that appear as red or purple marks on the skin. For most infants, these marks grow quickly during the first few months of life and then slowly fade away on their own over several years. However, a difficult subset of these tumors becomes ulcerated, meaning the skin over the tumor breaks down and forms an open sore. These ulcers are painful, prone to infection, and can bleed, leaving behind permanent scars. The challenge becomes even more complex when these tumors are part of a rare, multi-system condition called PHACE syndrome, where the large facial birthmark is accompanied by abnormalities in the brain, eyes, heart, and arteries. Treating these complicated cases has long been a balancing act for doctors, who must stop the tumor from growing and heal the sore without causing new harm, especially when the child's blood vessels are already fragile or misshapen.

For decades, the medical approach to these difficult lesions relied on single treatments, often starting with a drug called propranolol, which helps shrink the blood vessels by blocking specific signals in the body. While effective for many, some ulcers heal too slowly with this drug alone, leaving the infant in pain for too long. Other doctors have tried adding a short course of steroids to calm the inflammation, or using a specialized light therapy called pulsed dye laser to target the surface blood vessels directly. Until now, there has been little evidence on what happens when these three powerful tools are used together at the same time, particularly in the most severe cases involving PHACE syndrome. A new report from a team of researchers in Lebanon and the United Kingdom details exactly this experiment, showing how combining these methods can transform the outcome for infants with the most stubborn and dangerous skin tumors.

The researchers followed the journeys of three very young patients, all of whom arrived with large, painful ulcers on their skin. One was a three-month-old girl with a massive tumor covering the right side of her face and lip; another was a four-month-old with a similar growth spreading across her shoulder and chest; and the third was a one-month-old baby girl diagnosed with PHACE syndrome, whose tumor was accompanied by serious eye and brain artery abnormalities. In each case, the medical team decided to try a simultaneous, three-pronged attack. They began by giving the infants oral prednisone, a steroid medication, to quickly reduce swelling and inflammation. At the same time, they started a carefully monitored course of propranolol to slow the growth of the blood vessels. Finally, they added sessions of pulsed dye laser therapy, a treatment that uses a specific wavelength of light to gently heat and seal the tiny, leaking blood vessels on the surface of the wound without damaging the surrounding healthy skin.

The results were striking. In all three infants, the combination of treatments worked faster and more completely than previous methods had suggested was possible. The open sores on their skin began to close and heal, a process known as re-epithelialization, within weeks rather than months. The pain subsided, the bleeding stopped, and the tumors themselves began to shrink significantly. Perhaps most importantly, the treatment was safe even for the baby with the complex PHACE syndrome. Because this condition involves irregularities in the brain's blood supply, doctors had historically been hesitant to use propranolol, fearing it might cause a stroke by restricting blood flow too much. In this case, the team introduced the drug slowly and with extreme caution, clearing it with neurologists and cardiologists first. The infant tolerated the medication perfectly, showing no signs of neurological trouble, and continued to grow and develop normally.

The success of this approach lies in how the three treatments support one another. The steroid acts quickly to calm the angry, inflamed tissue, creating a better environment for healing. The propranolol works deeper within the tumor to stop the blood vessels from multiplying and to encourage them to shrink. The laser therapy acts on the surface, sealing the broken skin and reducing the redness that often remains after a tumor fades. By attacking the problem from these different angles at once, the team achieved a result that is greater than the sum of its parts. The infants did not just survive the ulceration; they healed with far less scarring and a much better cosmetic appearance than might have been expected. The researchers noted that while the treatment required careful monitoring of weight and dosage, the infants handled the regimen well, with no serious side effects reported.

This small series of cases offers a new blueprint for handling some of the most difficult skin tumors in infancy. It suggests that when a lesion is large, ulcerated, or part of a complex syndrome, waiting to see if a single drug will work might not be the best strategy. Instead, bringing together systemic medication, anti-inflammatory drugs, and targeted light therapy early in the process can lead to rapid recovery and better long-term results. While the study involved only three patients and cannot yet be called a final solution for every case, it provides strong, practical evidence that this combined approach is safe and effective. For parents facing the distress of a painful, bleeding birthmark on their child, and for the doctors who treat them, these findings offer a hopeful path forward, turning a potentially scarring and painful ordeal into a manageable journey toward healing.